News

Roche Enters Definitive Merger Agreement to Acquire Poseida Therapeutics

November 29, 2024

The acquisition will provide Roche with access to Poseida’s GMP manufacturing capabilities and R&D portfolio assets, including cell therapy candidates.

Adragos Pharma Strengthens Sterile Manufacturing Capabilities with Baccinex Acquisition

November 28, 2024

Through this acquisition, the German CDMO expands its global network and adds aseptic fill/finish and lyophilization expertise to its sterile manufacturing capabilities.

FDA Grants Approval to Kedrion to Produce PLGD-1 Therapeutic at Bolognana Plant

November 23, 2024

FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.

Fujifilm's Cell Therapy Facility Expansion Completed

November 23, 2024

The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.

Pii Boosts Prefilled Syringe Capabilities with $3.6 Million Investment

November 23, 2024

The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.

Abzena Expands Analytical Services with GMP Cell-Based Potency Testing in US and UK

November 22, 2024

The company has expanded its early and late phase analytical capabilities by including GMP cell-based potency assays at its sites in Cambridge, UK, and San Diego, Calif.

Sanofi Grows Antibody Production in France with €40 Million Investment

November 22, 2024

Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.

Circio and Certest to Collaborate on LNP Formulations

November 21, 2024

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Three New European Facilities Established by BioPharmaSpec for R&D

November 21, 2024

Located in German, Italy, and Lithuania, the new European facilities will specialize in drug discovery and R&D services.

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

November 20, 2024

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.